SLC16A7 and ovarian cancer: For RFS as well as OS, higher expression of SLC16A1 was associated with better survival in ovarian cancer patients (HR 0.68, p = 0.007 for OS, HR 0.058, p = 0.0059 for RFS), while SLC16A7 and SLC16A8 did not show any significant relation with either OS or RFS in ovarian cancer patients.